MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Second-Generation, Optional Vena Cava Filter
A 90-day update on the safety and performance of a second-generation, optional vena cava filter in an animal model.
By Bob Smouse, MD; Anthony O. Ragheb, PhD; and Shivani G. Patel, MD
Evaluating the Zilver PTX Stent
Principal investigators discuss the clinical study design and initial results with the Zilver PTX drug-eluting peripheral stent in the SFA.
By Michael D. Dake, MD; Gary M. Ansel, MD, FACC; and Anthony O. Ragheb, PHD
Two-Year SFA Data Presented for Cook's Zilver PTX Stent
May 7, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of interim results showing that patients with peripheral artery disease in the superficial femoral artery (SFA) treated with the Zilver PTX paclitaxel-eluting peripheral stent (Cook Medical, Bloomington, IN) maintained clinical improvement at 2 years.
Interim 2-Year SFA Data Presented for Cook's Zilver PTX Stent
May 7, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of interim results showing that patients with peripheral artery disease in the superficial femoral artery (SFA) treated with the Zilver PTX paclitaxel-eluting peripheral stent (Cook Medical, Bloomington, IN) maintained clinical improvement at 2 years.
Cook Medical's 2-Year Zilver PTX Trial Results Presented at ISET
January 17, 2011—Cook Medical (Bloomington, IN) announced that principal investigator Michael Dake, MD, presented 2-year results of the Zilver PTX trial at the International Symposium on Endovascular Therapy (ISET) in Miami Beach, Florida.
